Initial Clinical Data from Phase 1 Autoimmunity Study of FT819 1XX CAR T-cell Product Candidate to be Presented in 4Q24; ...

EZZ Life Science, Race Oncology and Orthocell are among ASX health companies reporting strong quarterly results this week.

These regimens tend to be less aggressive than traditional myeloablative therapies. The specific regimens mentioned include: Fludarabine plus Melphalan: A combination of 2 drugs used for conditioning.

A new research paper titled "ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells" has been published in Oncotarget.